Nothing Special   »   [go: up one dir, main page]

Latest News for: endocrine

Edit

Nationally Recognized Leader in Neuroendocrine and Endocrine Tumors Joins the TGH Cancer Institute

Longview News-Journal 12 Feb 2025
Dr. Boris Naraev specializes in the treatment and research of patients with gastrointestinal, neuroendocrine and endocrine cancers ....
Edit

Ascendis Pharma, a global biopharmaceutical company specialising in rare endocrine and other diseases, opens new office for the UK and Ireland

Pharmiweb 12 Feb 2025
Our experienced senior leadership team is testament to our commitment to making a meaningful difference for patients living with rare endocrine diseases in the UK and the Republic of Ireland.”.
Edit

Hospital for Endocrine Surgery Celebrates the Best Surgeons in the World with Castle Connolly Recognition

PR Newswire 11 Feb 2025
Gary Clayman Recognized as Top Specialists in Endocrine Surgery ... Clayman's inclusion in this exclusive group speaks to their unparalleled expertise and dedication to advancing endocrine surgery ... The Hospital for Endocrine Surgery.
Edit

The 'Healing' Vibes of 528Hz: Enhancing Endocrine Balance and Well-Being

Rumble 08 Feb 2025
Go to the source via the article link to view the video or click the video icon ....
Edit

Langer Medical Announces Platinum Sponsorship of Eurocrine, the European Registry for Endocrine Surgery

Pharmiweb 29 Jan 2025
This strategic partnership underscores the company’s ongoing commitment to advancing the field of endocrine surgery through innovation and expertise ... patient safety and precision in endocrine surgery.
Edit

Enhertu approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies

Pharmiweb 28 Jan 2025
Endocrine therapy is typically used in the initial treatment of HR-positive metastatic breast cancer and following progression, subsequent chemotherapy is associated with poor outcomes.
Edit

Enhertu approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies (Form 6-K) (AstraZeneca plc)

Public Technologies 28 Jan 2025
Enhertu approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies.
Edit

RFK Jr.'s approach to toxics could unite Republicans and Democrats

The Hill 28 Jan 2025
With Robert F ... And he’s not wrong ... Kennedy suggests the environmental movement has all but forgotten about toxics and endocrine-disrupting and cancer-causing chemicals that are infiltrating our heads, hearts, hormones and habitats ... ....
Edit

Enhertu approved in the US as first HER2 directed therapy for patients with HER2 low or HER2 ultralow metastatic breast cancer following disease progression after one or more endocrine therapies (AstraZeneca plc)

Public Technologies 27 Jan 2025
"Endocrine therapy is typically used in the initial treatment of HR-positive metastatic breast cancer and following progression, subsequent chemotherapy is associated with poor outcomes ... Updates in endocrine therapy for metastatic breast cancer.
Edit

ENHERTU® Approved in the U.S. as First HER2 Directed Therapy for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following Disease Progression After One or More Endocrine Therapies (Daiichi Sankyo Co Ltd)

Public Technologies 27 Jan 2025
"The approval also highlights the importance of testing metastatic breast cancer tumors for detectable staining with a standard IHC test to identify those who may be eligible for treatment with ENHERTU following endocrine therapy.".
Edit

ENHERTU® (fam trastuzumab deruxtecan nxki) approved in the US as first HER2 directed therapy for patients with HER2 low or HER2 ultralow metastatic breast cancer following disease progression after one or more endocrine therapies (AstraZeneca Pharmaceuticals LP)

Public Technologies 27 Jan 2025
"Endocrine therapy is typically used in the initial treatment of HR-positive metastatic breast cancer and following progression, subsequent chemotherapy is associated with poor outcomes ... Updates in endocrine therapy for metastatic breast cancer.
  • 1
×